Trop2-ADCs are safe and tolerable in advanced breast cancer, with differences in the toxicity profiles among different Trop2-ADC drugs. Overall, Dato-DXd demonstrates superior safety in terms of treatment-related adverse events (TRAEs) and hematological toxicity compared to other Trop2-ADCs, but gastrointestinal adverse reactions need to be monitored. Hematological toxicity and diarrhea are the most common adverse events for sacituzumab govitecan (SG), occurring at higher rates than with other Trop2-ADCs. Liver toxicity associated with SKB264 also requires attention. In terms of efficacy, the progression-free survival (PFS) of Dato-DXd and SKB264 is superior to that of SG, although SG appears to have an advantage in overall survival (OS).
Trop2-ADC药物在晚期乳腺癌中的安全性与疗效分析
本文深入分析Trop2-ADC药物在晚期乳腺癌治疗中的安全性与疗效,对比Dato-DXd、sacituzumab govitecan和SKB264的不良反应与生存期数据,提供最新临床研究证据与治疗建议。
与梅斯小智对话